Kirsten E. Fleischmann
Abstract
Recent studies have suggested an interaction between clopidogrel and proton-pump inhibitors (PPIs) that might attenuate clopidogrel activity. To assess the clinical relevance of this interaction, researchers studied 18,000 people (age, ≥65) in the U.S. and Canada who had been newly treated with clopidogrel after acute coronary …
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Recent studies have suggested an interaction between clopidogrel and proton-pump inhibitors (PPIs) that might attenuate clopidogrel activity. To assess the clinical relevance of this interaction, researchers studied 18,000 people (age, ≥65) in the U.S. and Canada who had been newly treated with clopidogrel after acute coronary …
Key concepts: Clopidogrel, Medicine, CYP2C19, Proton-pump inhibitor, Clinical significance, Acute coronary syndrome, Internal medicine, Cardiology